An Open-Label, Phase 2 Trial of Nanatinostat in Combination with Valganciclovir in Patients with Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas (NAVAL-1)
To evaluate the anti-tumor activity of the combination treatment of nanatinostat (Nstat) with valganciclovir (VGCV) based on objective tumor response rates.
University of Colorado Hospital
Brad Haverkos, MD
Protocol Number: 22-0565
More information available at ClinicalTrials.gov: NCT05011058
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers